However, it remains unclear whether TAC-induced diabetes is associated with incretin dysfunction, and whether the tissue-protective effects of DPP IV inhibitors are also effective in TAC-induced pancreatic islet cell injury. The gene discussed is DPP4; the disease is diabetes mellitus.